LifeMD (LFMD) Stock Forecast & Price Target

LifeMD Inc. reported a 14% year-over-year growth in its Telehealth active subscriber base, reaching 310,818 by the end of the third quarter of 2025, showcasing a resurgence in demand for its services. The company generated total revenue of $60.2 million, reflecting a 12.7% year-over-year increase, with Telehealth revenue specifically rising by 17.4% to $47.3 million, despite missing initial projections. Notably, the company has made significant investments in its telehealth infrastructure and is capitalizing on growing market demand for new products, such as its planned offering of GLP-1 medications, indicating a positive trajectory for future growth.

LifeMD Inc reported a revenue of $60.2 million for the quarter, reflecting a 13% year-over-year increase but falling short of analyst expectations, which ranged from $61 million to $62.6 million. The company also experienced a decline in its WorkSimpli segment, with revenue dropping 1.7% year-over-year to $12.9 million, contributing to an overall disappointing financial performance as adjusted EBITDA also missed guidance. Additionally, concerns regarding slowing growth in the Telehealth segment, increased competition impacting pricing, and a revised revenue forecast for FY2025 indicate significant challenges that could adversely affect LifeMD's stock outlook.